Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 20, 2014 (12 years ago)

Mesalamine

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Particulate Matter: Stainless steel in a chemical reactor dissolved into the API solution and was detected in the finished product.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Mesalamine, U.S.P. [CAS 89-57-6] Cambrex Charles City, Inc. Charles City, IA packaged in double lined PE liners inside Poly-lined cardboard drums. Net weight 40 kg

Drug: Mesalamine

Recalling firm
Cambrex Charles City Inc
Origin
IA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0447-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Mesalamine recalls

See all
Class II · Moderate risk

Mesalamine Delayed-Release Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 63304-175-13 D-0268-2024
Class II · Moderate risk

Mesalamine Delayed-Release Tablets

Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing.

Terminated Dissolution failure Teva Pharmaceuticals USA NDC 0591-2245-22 D-0069-2021
Class II · Moderate risk

Mesalamine Delayed-Release Tablets

Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing.

Terminated Dissolution failure Teva Pharmaceuticals USA NDC 0591-2245-22 D-0862-2020

Other particulate / foreign matter recalls from 2014

All particulate / foreign matter recalls
Class II · Moderate risk

Propofol Injectable Emulsion

Presence of Particulate Matter: The firm received a complaint of an embedded particulate in the neck of one vial composed primarily of iron.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4699-30 D-0381-2015
Class I · High risk

0.9% Sodium Chloride Injection USP

Presence of Particulate Matter: Confirmed customer complaints received for the presence of blue plastic, identified as fragments of the frangible from the vial adapter.

Terminated Particulate / foreign matter Baxter Healthcare Corp NDC 0338-0553-18 D-481-2015